Discontinuation of immunosuppression. Time to discontinuation of immunosuppression is prolonged among patients who received mobilized peripheral blood (B), among male recipients with female donors (C), and among patients with HLA disparity (D). Panel A shows the cumulative incidence of discontinued immunosuppressive treatment without recurrent malignancy (lower curve and left-hand scale) and the competing risks of death or recurrent malignancy during continued immunosuppressive treatment (upper curve and right-hand scale) among all patients. Other panels show the same results for patients with (– – –) or without (—) the indicated risk factor. In panel C, results for female recipients with either male or female donors were similar to those for male recipients with male donors.